Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Toho: Sales Up 9.1% Boosted by Addition of SAYWELL
November 22, 2010
- EFPIA Survey Shows “Over-Quality” of Clinical Trials in Japan
November 22, 2010
- Daiichi Sankyo to Independently Market Memantine
November 15, 2010
- Otsuka Changes Articles of Incorporation
November 15, 2010
- All-Patient Drug Use-Result Survey on Humira Completed
November 15, 2010
- Combined Half-Year Sales of Top-Eight Domestic Firms Up 1.8%
November 15, 2010
- Nippon Kayaku Ties Up with Celltrion to Develop Herceptin, Remicade Biosimilars
November 15, 2010
- Osteoporosis GL to Be Revised in 2011
November 15, 2010
- Astellas: Sales, Profits Down Due to Prograf Patent Expiration
November 15, 2010
- Savings by Generic Substitutionto to Taper Off: Mr Masuhara
November 15, 2010
- GSK Reduces Price of Cervarix by 30% in Canada
November 15, 2010
- Taisho: Sales Down 1% for Pharma, Up 4.6% for Self-Med
November 15, 2010
- Korosho OKs Continued Sale of Mylotarg in Japan
November 15, 2010
- Eisai to Increase Market Share for Higher-Strength Aricept
November 15, 2010
- Shionogi: Sales Up 8.1%, Net Profits Down 40.8%
November 15, 2010
- Crohn's Disease, Ankylosing Spondylitis Approved for Humira: Abbott, Eisai
November 15, 2010
- MTPC, Korosho Discussing Resumptionof of Marketing for Medway Inj.
November 15, 2010
- Ono: Sales Down 5.1% Due to Price Cuts, Competition with Generics
November 15, 2010
- Chuikyo Appreciates Efforts Made to Develop, Apply for Unapproved Drugs/Indications
November 15, 2010
- Shionogi Confident about Its Marketing Strategy in Japan
November 15, 2010
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…